MCL Literature Feed

Italian real-world data highlights the poor prognosis and significant unmet clinical needs for relapsed/refractory MCL patients following covalent BTKi failure, emphasizing the urgency for novel treatment strategies.

This paper outlines strategies for improved collaboration between community oncologists and authorized centers to overcome logistical and educational barriers, ensuring timely referral and access to CAR-T therapy for MCL.

A novel SRC-3 inhibitor, SI-10, demonstrates preclinical efficacy in ibrutinib-resistant MCL models, identifying SRC-3 as a potential therapeutic target to overcome BTKi resistance.

This systematic review of real-world data supports positioning covalent BTKis as second-line therapy for relapsed/refractory MCL, followed by CAR-T cells for patients relapsing after BTKi treatment.

This review details the pathophysiology and management of CAR-T toxicities like CRS and ICANS, providing essential guidance for clinicians treating relapsed/refractory MCL patients with this therapy.

This review consolidates efficacy and toxicity data for FDA-approved CAR-T products in aggressive B-cell lymphomas, including MCL, serving as a practical guide for this established relapsed/refractory treatment.

This meta-analysis of 984 R/R MCL patients confirms high CAR-T efficacy (74% CR, 69% 1-year OS), providing robust, pooled outcome data for this heavily pretreated population.

This indirect comparison shows acalabrutinib has a superior safety profile to ibrutinib in relapsed/refractory MCL with similar efficacy, supporting its preferential use in this setting.

This case report identifies therapy-related acute myeloid leukemia as a serious long-term toxicity after brexucabtagene autoleucel, highlighting the need for post-CAR-T surveillance for secondary malignancies.

This case of classical MCL rapidly transforming to a blastoid variant with CNS involvement highlights the poor prognosis and failure of BTKi and chemotherapy in this aggressive setting.

In a real-world cohort including MCL, the Hematotox-Score predicted early cytopenias post-CAR-T but not survival, underscoring the need for improved prognostic tools for toxicity management.